Clinical trial
A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
NCT04370587 is registered in ClinicalTrials.gov with ImmVira Pharma Co. Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
- Lead sponsor
- ImmVira Pharma Co. Ltd
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- September 17, 2020
- Completion date
- January 10, 2027
- Enrollment
- 30 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.